174 related articles for article (PubMed ID: 21447351)
1. Association between breast cancer subtypes and response to neoadjuvant anastrozole.
Dunbier AK; Anderson H; Ghazoui Z; Salter J; Parker JS; Perou CM; Smith IE; Dowsett M
Steroids; 2011 Jul; 76(8):736-40. PubMed ID: 21447351
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
[TBL] [Abstract][Full Text] [Related]
3. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
Ma CX; Suman VJ; Sanati S; Vij K; Anurag M; Leitch AM; Unzeitig GW; Hoog J; Fernandez-Martinez A; Fan C; Gibbs RA; Watson MA; Dockter TJ; Hahn O; Guenther JM; Caudle A; Crouch E; Tiersten A; Mita M; Razaq W; Hieken TJ; Wang Y; Rimawi MF; Weiss A; Winer EP; Hunt KK; Perou CM; Ellis MJ; Partridge AH; Carey LA
JAMA Oncol; 2024 Mar; 10(3):362-371. PubMed ID: 38236590
[TBL] [Abstract][Full Text] [Related]
4. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
5. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
6. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Polychronis A; Sinnett HD; Hadjiminas D; Singhal H; Mansi JL; Shivapatham D; Shousha S; Jiang J; Peston D; Barrett N; Vigushin D; Morrison K; Beresford E; Ali S; Slade MJ; Coombes RC
Lancet Oncol; 2005 Jun; 6(6):383-91. PubMed ID: 15925816
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
[TBL] [Abstract][Full Text] [Related]
8. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Miller WR; Larionov A
Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
[TBL] [Abstract][Full Text] [Related]
9. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
[TBL] [Abstract][Full Text] [Related]
10. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Dunbier AK; Ghazoui Z; Anderson H; Salter J; Nerurkar A; Osin P; A'hern R; Miller WR; Smith IE; Dowsett M
Clin Cancer Res; 2013 May; 19(10):2775-86. PubMed ID: 23493347
[TBL] [Abstract][Full Text] [Related]
12. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Murray J; Young OE; Renshaw L; White S; Williams L; Evans DB; Thomas JS; Dowsett M; Dixon JM
Breast Cancer Res Treat; 2009 Apr; 114(3):495-501. PubMed ID: 18438705
[TBL] [Abstract][Full Text] [Related]
13. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M
Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703
[TBL] [Abstract][Full Text] [Related]
14. Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Schmid P; Pinder SE; Wheatley D; Macaskill J; Zammit C; Hu J; Price R; Bundred N; Hadad S; Shia A; Sarker SJ; Lim L; Gazinska P; Woodman N; Korbie D; Trau M; Mainwaring P; Gendreau S; Lackner MR; Derynck M; Wilson TR; Butler H; Earl G; Parker P; Purushotham A; Thompson A
J Clin Oncol; 2016 Jun; 34(17):1987-94. PubMed ID: 26976426
[TBL] [Abstract][Full Text] [Related]
15. Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao Q; López-Knowles E; Cheang MCU; Morden J; Ribas R; Sidhu K; Evans D; Martins V; Dodson A; Skene A; Holcombe C; Mallon E; Evans A; Bliss JM; Robertson J; Smith I; Martin LA; Dowsett M;
Breast Cancer Res; 2019 Dec; 22(1):2. PubMed ID: 31892336
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.
Schuster EF; Lopez-Knowles E; Alataki A; Zabaglo L; Folkerd E; Evans D; Sidhu K; Cheang MCU; Tovey H; Salto-Tellez M; Maxwell P; Robertson J; Smith I; Bliss JM; Dowsett M
Nat Commun; 2023 Jul; 14(1):4017. PubMed ID: 37419892
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors: cellular and molecular effects.
Miller WR; Anderson TJ; White S; Larionov A; Murray J; Evans D; Krause A; Dixon JM
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):83-9. PubMed ID: 16002280
[TBL] [Abstract][Full Text] [Related]
18. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
[TBL] [Abstract][Full Text] [Related]
20. Molecular response to aromatase inhibitor treatment in primary breast cancer.
Mackay A; Urruticoechea A; Dixon JM; Dexter T; Fenwick K; Ashworth A; Drury S; Larionov A; Young O; White S; Miller WR; Evans DB; Dowsett M
Breast Cancer Res; 2007; 9(3):R37. PubMed ID: 17555561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
